title: Lung ischemia reperfusion injury: a bench-to-bedside review.
abstract: Lung ischemia reperfusion injury (LIRI) is a pathologic process occurring when oxygen supply to the lung has been compromised followed by a period of reperfusion. The disruption of oxygen supply can occur either via limited blood flow or decreased ventilation termed anoxic ischemia and ventilated ischemia, respectively. When reperfusion occurs, blood flow and oxygen are reintroduced to the ischemic lung parenchyma, facilitating a toxic environment through the creation of reactive oxygen species, activation of the immune and coagulation systems, endothelial dysfunction, and apoptotic cell death. This review will focus on the mechanisms of LIRI, the current supportive treatments used, and the many therapies currently under research for prevention and treatment of LIRI.
authors.affiliation: College of Physicians and Surgeons of Columbia Presbyterian Hospital, New York, NY, USA.
authors.forename: Paul D
authors.initials: PD
authors.lastname: Weyker
authors.forename: Christopher A J
authors.initials: CA
authors.lastname: Webb
authors.forename: David
authors.initials: D
authors.lastname: Kiamanesh
authors.forename: Brigid C
authors.initials: BC
authors.lastname: Flynn
mesh_terms: D056704:Adaptive Immunity; D003167:Complement Activation; D006801:Humans; D006931:Hyperbaric Oxygenation; D007113:Immunity, Innate; D008168:Lung / Q000098:blood supply*; D019001:Nitric Oxide Synthase / Q000502:physiology; D017382:Reactive Oxygen Species / Q000378:metabolism; D015427:Reperfusion Injury / Q000209:etiology / Q000276:immunology / Q000628:therapy*
chemical_list: D017382:Reactive Oxygen Species; D019001:Nitric Oxide Synthase